The company will use the proceeds to advance its pipeline of TGF-β inhibitors that stimulate the human immune system to effectively fight cancer.
MIG Verwaltungs managing director Matthias Kromayer said, “MIG is convinced that an immunotherapy approach to treating cancer has the potential to change the paradigm of current standard of care.
“We have great confidence in both Isarna’s pioneering approach to leveraging TGF-β and the company’s management.”
Recent venture capital deals in Germany include Star Ventures Funds’s sale of 20 assets to secondary direct investor Saints Capital.
Copyright © 2014 AltAssets